+26.2%
DAL vs MRNA
+171.6%
-145.4%
-18.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.8% | -2.2% | +4.0% | +1.8% |
| 7D | +0.1% | +5.5% | -5.4% | +0.1% |
| 30D | -13.9% | +158.7% | -172.7% | -15.3% |
| 3M | +1.1% | +182.1% | -181.0% | -6.5% |
| 6M | +26.2% | +151.8% | -125.6% | +24.3% |
| All | +26.2% | +171.6% | -145.4% | +24.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling